

# Texas HIV Medication Program Medication Advisory Committee Meeting

July 12, 2024

### **DSHS Updates**

Josh Hutchison
Associate Commissioner
Infectious Disease Prevention Division

#### **THMP Roadmap**

- Agency
  - THMP Rising Cost Projections
  - Future Deficit
- Long Acting Injectables Cabenuva
- Financial Forecast (Rebates)
  - ► Inflation Reduction Act (IRA)
  - ► Medicare Changes
  - ► State Pharmacy Assistance Program (SPAP)
  - ► Impact to Rebates
- Budget Report



**Health Services** 

# THMP Historical and Projected Cost Increases

Fiscal Year	ADAP Medications Only		SPAP		TIAP		Total	
FY	Clients	Total	Clients	Total	Clients	Total	Clients*	Total
FY20	20,895	\$137,159,393	2,138	\$8,228,865	457	\$991,576	23,490	\$146,379,834
FY21	21,892	\$118,204,285	2,084	\$8,175,902	416	\$923,271	24,392	\$127,303,459
FY22	15,208	\$78,800,482	1,787	\$7,519,290	273	\$635,088	17,268	\$86,954,860
FY23	18,197	\$96,606,784	1,722	\$7,535,130	182	\$525,034	20,101	\$104,666,949
FY24	21,308	\$124,610,748	1,652	\$6,543,365	220	\$651,172	23,180	\$131,805,285
FY25	21,521	\$131,383,619	1,652	\$6,661,145	222	\$670,838	23,395	\$138,715,602
FY26	21,736	\$131,122,000	1,652	\$6,781,046	225	\$691,097	23,613	\$138,594,143
FY27	21,736	\$131,122,000	1,652	\$6,903,105	227	\$711,968	23,615	\$138,737,073



Texas Department of State Health Services

DSHS operated at a deficit in 2020. The program cannot sustain THMP when ADAP costs are at or above \$130 million.

Data from May 2024 Projections. Data for June 2024 – August 2027 are based on projections.

# DSHS Projects an ADAP Medication Deficit by 2025

Projected Medication	FY24 Projections	FY25 Projections	FY26 Projections	FY27 Projections
Costs by Year	\$124.6 million	\$131.3 million	\$131.1 million	\$131.1 million
ADAP Medication	FY24 Budget	FY25 Projected	FY26 Projected	FY27 Projected
Budget by Year before				
Rebate Reduction	\$131.6 million	\$106.4 million	\$106.4 million	\$106.4 million
Expected Rebates after	FY24 Rebates	FY25 Projected	FY26 Projected	FY27 Projected
Reduction by Year	\$23.8 million	\$7.0 million	\$4.3 million	\$4.3 million
Projected Budget after	FY24 Funds	FY25 Projected	FY26 Projected	FY27 Projected
Rebate Reduction	\$131.6 million	\$96.0 million	\$93.2 million	\$93.2 million
Remaining	FY24 Funds	FY25 Projected	FY26 Projected	FY27 Projected
Funding/Deficit by Year*	\$7.0 million	(\$35.4 million)	(\$37.8 million)	(\$37.8 million)

TEXAS
Health and Human
Services

<sup>\*</sup>Does not account for existing inventory within the DSHS Pharmacy

#### **THMP Budget Overview: Summary**

- THMP is rolling towards a fiscal cliff due to three primary drivers beyond the control of DSHS:
  - ► Federal and national policy changes
  - ► Projected increased client growth and related medication costs
  - ▶ Other factors unique to Texas compared to other state ADAPs



#### **Cost Driver: Factors Unique to Texas**

- What other states may have that Texas does not:
  - ▶ Not as reliant on Medicare rebates
  - ► Expanded insurance purchasing
  - ► Fewer people living with HIV
  - ► Different support service models, which could include the expansion of Medicaid
  - ► Less reliant on federal supplemental dollars
- THMP cannot expand insurance purchasing
  - ► During the 87<sup>th</sup> Legislative session, DSHS requested to expand insurance purchasing
  - ► Rider 26 language specifically authorizing a pilot to expand insurance purchasing was struck



#### Long Acting Injectables - Cabenuva

- Rider 36 Analysis (88<sup>th</sup> Legislative session)
  - ▶ Was contingent on the availability of federal funding
  - ► Needed an update to take account for factors discussed at the last MAC meeting
  - ▶ Needs longer-term discussion to consider the possibility of other long-acting injectables coming to market in the near future
- DSHS conducted a financial review of THMP to access its ability to include it in the THMP formulary



#### **Next Steps: DSHS Analysis Continues**

- Can THMP resolve this projected fiscal cliff without legislative intervention or additional state funding?
- Are there structural changes to the program that do not impact the number of clients served and can ensure stability?
- Does DSHS need to refine its insurance purchasing analysis?



### Rebates


Rachel Sanor
Medications and Care Services Unit Director
HIV/STD Section

#### **Overview of Medicare Program**

- The standard Part D
   prescription drug benefit
   consists of four sequential
   coverage phases: deductible,
   initial coverage, coverage gap,
   and catastrophic coverage
   phases
- Progression through the first two coverage phases (deductible and initial coverage) is based on total gross covered prescription drug costs, which refers to spending on covered Part D drugs by beneficiaries or on their behalf by any third party as well as the Part D sponsor
- Clients may elect to enroll in a Part D or Medicare Advantage Plan for prescription assistance from Medicare. SPAP only has the mechanism to pay for Part D plans
- Historically, Medicare includes dual-eligible Medicaid and Medicare, full low-income subsidy (LIS), and partial LIS for low-income Medicare participants. SPAP does not cover dual-eligible or full-LIS participants



# Medicare Changes-Inflation Reduction Act (IRA)



**Health Services** 

#### **How Medicare Changes Will Impact THMP**

### **Elimination of Partial Low-Income Subsidy**

- Expand eligibility for full benefits under the Medicare Part D Low-Income Subsidy (LIS) Program
- Those with incomes between 135-150% of the FPL will move from partial LIS to full LIS

#### **Impact to THMP Rebates**

- THMP does not cover participants with Full LIS. This will reduce the SPAP eligibility pool to those with 150% FPL up to 200%
- This will decrease SPAP claims by 9%
- The impact started in January 2024. Rebates from this time period were received starting in June 2024.

#### **How Medicare Changes Will Impact THMP**

### **Eliminating Cost Sharing for Catastrophic Phase of Coverage**

- There is no cost sharing for covered Part D drugs above the annual out-of-pocket (OOP) threshold for any Part D beneficiaries
- Will eliminate cost sharing for covered Part D drugs for beneficiaries in the catastrophic phase of coverage

#### **Impact to THMP Rebates**

- In (2024), the catastrophic threshold is \$8,000. This amount includes what Part D enrollees spend out-of-pocket plus the value of the manufacturer price discount on brands in the coverage gap phase. This lowers the total out-of-pocket cost to \$3,300
- In (2023), 52.6% of SPAP claims were greater than \$3,300
- The impact started in January 2024 Rebates from this time period were received starting in June 2024

#### **How Medicare Changes Will Impact THMP**

#### **New Out of Pocket Threshold**

 The Out-of-Pocket Threshold is set at \$2,000

#### **Impact to THMP Rebates**

- This will result in a 68.8% reduction in SPAP Claims
- The impact will start in January 2025. Rebates from this time period will be received starting in June 2025.

# **Cost Driver: Federal and National Policy Changes - Inflation Reduction Act (IRA)**

- Rebates generated from (2024), which THMP received starting in June 2024, will decrease by 59.2%
  - ▶ 8.7% because of the elimination of the partial low-income subsidy
  - ► 50.5% due to the elimination of cost sharing in the catastrophic coverage phase of coverage
- Rebates generated from (2025), which THMP will receive starting June 2025, will decrease by 75.4%
  - ▶ 8.7% because of the elimination of the partial low-income subsidy
  - ▶ 66.7% due to the out-of-pocket threshold of \$2,000



# **Cost Driver: Federal and National Policy Changes**

### Medicare and the Inflation Reduction Act


- THMP serves a small client base within the State Pharmacy Assistance Program (SPAP) program
- SPAP serves clients by paying for out-of-pocket costs associated with Medicare Part D (prescription drug) policies
- SPAP generates the lion's share of medication revenue rebate for the entirety of THMP
- Recent changes to Medicare via the Inflation Reduction Act will significantly impact rebate revenue

FY	Number of SPAP Enrollees	%
FY20	2,138	82%
FY21	2,084	83%
FY22	1,787	87%
FY23	1,722	90%

Time Period	Number of SPAP Claims	%	
(2022-Q3)	19,600	97%	
	·		
(2022-Q4)	19,215	98%	
(2023-Q1)	17,280	96%	
(2023-Q2)	18,642	97%	
Total	74,737	97%	



# Cost Driver: SPAP and TIAP Cost vs. Rebate Revenue Generated



### **Budget Report**

**D'Andra Luna, MPH**Section Director
HIV/STD Section



#### **Monthly THMP Financial Report**

Budget Description	2023*	2024*	2024*	2024*	2024*
buuget Description	Expended	Budgeted	Obligated	Expended	Remaining
General Revenue (GR)	\$3,753,341	\$244,775	\$244,775	\$0	\$244,775
GR Match/MOE	\$2,471,807	\$2,471,807	\$2,471,807	\$2,038,785	\$433,022
HIV Vendor Drug Rebates	\$21,423,897	\$23,873,713	\$23,873,713	\$23,873,713	\$0
Federal Care Grants	\$95,776,777	\$104,896,339	\$104,896,339	\$77,212,094	\$27,684,245
Program Income	\$0	\$121,930	\$121,930	\$121,930	\$0
Total All Funds	\$123,425,822	\$131,608,564	\$131,608,564	\$103,246,522	\$28,362,042



**Health Services** 

<sup>\*</sup>State Fiscal Year: September 1 – August 31 annually.

# Monthly THMP Annualized Medication Budget

Budget Description	Annualized Amount
General Revenue (GR)	\$0
GR Match/MOE	\$2,471,807
HIV Vendor Drug Rebates	\$23,873,713
Federal Care Grants	\$79,705,550
Program Income	\$0
Total Budgeted Funds	\$106,051,070
FY24 Other Funds Used to Purchase Medications	\$25,557,494
Total All Funds in FY24	\$131,608,564

The annual medication planned for one year is roughly \$106 million dollars, annual budget adjustments may cause fluctuations each year. DSHS also allocates additional funds that are unused, those funds are not guaranteed.



**Health Services** 

### Thank you.